Immunobloting of FIS1 in primary refractory AML patients (1–5) and non-refractory AML patients (6–11). *P<0.05.

<p>Immunobloting of FIS1 in primary refractory AML patients (1–5) and non-refractory AML patients (6–11). *P<0.05.</p

Overall survival of patients with CN-AML according to different PDCD7 expression levels from published microarray data.

<p>Overall survival of patients with CN-AML according to different PDCD7 expression levels from published microarray data.</p

FIS1 and APP expression in different FAB subtypes. *P<0.05.

<p>FIS1 and APP expression in different FAB subtypes. *P<0.05.</p

Clinical features and treatment of 97 AML patients.

<p>AML acute myeloid leukemia, FAB French-American-British classification of acute myeloid leukemia, CN-AML cytogenetically normal acute myeloid leukemia, PB peripheral blood, BM bone marrow, CR, complete remission, DA daunorubicin and cytarabine, IA idarubicin and cytarabine, TA pirarubicin and cytarabine, MDAC/HDAC medium/high dose cytarabine, HSCT hematopoietic stem cell transplantation, Allo- allogeneic, Auto- autologous.</p><p>^a Patients received standard regimens from induction or <4 courses of MDAC/HDAC.</p><p>^b Patients received ≥4 courses of MDAC/HDAC or HSCT.</p

Univariate and multivariate analysis for OS in 59 CN-AML patients.

<p>CN-AML cytogenetically normal acute myeloid leukemia, HR hazard ratio, CI coefficient index, CR complete remission, P P values, PR partial remission, NR not remission.</p><p>High intensity treatment included patients received ≥4 courses of MDAC/HDAC or HSCT, and low intensity treatment included patients received standard regimens from induction or <4 courses of MDAC/HDAC in consolidation.</p

PDCD7 and KLRF1 expression range in AML (n = 97) and non-malignant controls (n = 30). *P<0.05.

<p>PDCD7 and KLRF1 expression range in AML (n = 97) and non-malignant controls (n = 30). *P<0.05.</p

The cumulative incidence of herpesvirus-associated CNS diseases.

<p>The cumulative incidence of herpesvirus-associated CNS diseases.</p